Immunovant, Inc.
The Director, TMF Operations at Immunovant leads the transformation and ongoing operations of the Trial Master File (TMF) to deliver a governed, inspection-ready model. The role focuses on strategy, quality, oversight, and inspection readiness, including governance, harmonized TMF definitions, and CRO model oversight.
Headquarters
New York, New York, United States
Company Size
201-500 employees
Founded
2018
Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted therapies to enable normal lives for people with autoimmune diseases. The company is a trailblazer in anti‑FcRn technology and is advancing a pipeline of candidates through clinical trials across multiple therapeutic areas. Immunovant emphasizes patient and caregiver support while providing investor resources and corporate information. Headquartered in New York, it is publicly traded under the ticker IMVT.
TD Asset Management Inc Sells 56,752 Shares of Immunovant, Inc. $IMVT
5 days ago
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update
6 days ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
3 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Immunovant, Inc..
29% above the average for this role
Immunovant Launches New Clinical Trials, Reports $599M Cash Position | IMVT Stock News
Aug 11, 2025